



1646

Patent

Attorney's Docket No. 002010-680

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of ) **BOX NON-FEE AMENDMENT**  
Konradi et al. )  
Application No.: 09/910,702 ) Group Art Unit: 1646  
Filed: July 20, 2001 ) Examiner: T.N. Truong  
For: ALPHA AMINO ACID DERIVATIVES- ) Confirmation No.: 2073  
INHIBITORS OF LEUKOCYTE )  
ADHESION MEDIATED BY VLA-4 )

**AMENDMENT/REPLY TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a reply for the above-identified patent application.

A Petition for Extension of Time is also enclosed.

A Terminal Disclaimer and a check for [ ] \$55.00 (2814) [ ] \$110.00 (1814) to cover the requisite Government fee are also enclosed.

Also enclosed is \_\_\_\_\_.

Small entity status is hereby claimed.

Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the [ ] \$370.00 (2801) [ ] \$740.00 (1801) fee due under 37 C.F.R. § 1.17(e).

Applicant(s) previously submitted \_\_\_, on \_\_\_, for which continued examination is requested.

Applicant(s) request suspension of action by the Office until at least \_\_\_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.

A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.

No additional claim fee is required.

RECEIVED  
NOV 22 2002  
TECH CENTER 1600/2900

[ ] An additional claim fee is required, and is calculated as shown below:

AMENDED CLAIMS					
	NO. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims		MINUS =		× \$18.00 (1202) =	
Independent Claims		MINUS =		× \$84.00 (1201) =	
If Amendment adds multiple dependent claims, add \$280.00 (1203)					
Total Amendment Fee					
If small entity status is claimed, subtract 50% of Total Amendment Fee					
<b>TOTAL ADDITIONAL FEE DUE FOR THIS AMENDMENT</b>					


[ ] A claim fee in the amount of \$ \_\_\_\_\_ is enclosed.

[ ] Charge \$ \_\_\_\_\_ to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Gerald F. Swiss  
Registration No. 30,113

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300

Date: November 15, 2002



#8  
11/29/02

Patent

Attorney's Docket No. 002010-680

*C. Steffes*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
Konradi, et al. ) Confirmation No. 2073  
Application No.: 09/910,702 ) Group Art Unit: 1646  
Filed: July 20, 2001 ) Examiner: T. N. Truong  
For: Alpha Amino Acid Derivatives- )  
Inhibitors of Leukocyte Adhesion )  
Mediated by VLA-4 )

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Reply is in response to the Office Action mailed September 23, 2002. This Office Action, in the form of an election of species requirement, set a one-month period for response. A Petition requesting a one-month extension of time accompanies this response which is being filed on or before its now current due date of November 23, 2002.

In response to this Office Action, consideration of the following remarks is earnestly solicited.


**R E M A R K S**

It is respectfully requested that the claims in this application be examined in view of the following remarks.


Election of Species Requirement

In this Office Action, it is alleged that the claims of this application are generic to a plurality of patentably distinct species disclosed in the application, corresponding to compounds of formulae Ia, Ib, IIa, IIb, IIc, IIId, and IIe.

In response to this requirement, Applicants elect, without traverse, the compounds of Group IIc which are represented by the formula:



In addition, if an ultimate species is required, Applicants elect, without traverse, the compound of example 1, i.e., *N*-(5-(2,2,2-trifluoroethyl)pyrimidin-4-yl)-L-4'-(1-methyl-4-methoxy-2-pyridon-3-yl)phenylalanine which is represented by the formula:



Reply and Amendment  
Application No. 09/910,702  
Attorney's Docket No. 002010-680  
Page 3

Applicants believe that Claims 1, 3, 6-12, 14 and 17-21 read on the elected species.

Early examination of this application is requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Gerald F. Swiss  
Gerald F. Swiss  
Registration No. 30,113

P.O. Box 1404  
Arlington, VA 22313-1404  
Firm Phone: (650) 622-2300

Date: November 15, 2002